On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104. Following this transaction, the insider now owns 22,400 shares of the company.
Annexon Inc focuses on the development of therapeutics for autoimmune and neurodegenerative disorders. The company's approach targets the classical complement pathway to prevent abnormal activation, which is a cause of these diseases.
Over the past year, William Carson has increased his holdings in the company by purchasing a total of 22,400 shares, with no recorded sales.
The insider transaction history at Annexon Inc shows a pattern of 8 insider buys and 16 insider sells over the past year. This recent purchase by Director William Carson could be seen as a positive signal within the context of the company's insider activity.
Shares of Annexon Inc were trading at $5.97 on the day of the transaction, giving the company a market cap of approximately $678.3 million.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further on GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
